XKRX:001067 (Korea (the Republic of))
Â
Pfd Shs Non-Voting
â‚©
58700.00
(-0.34%)
Jun 4
Business Description
JW Pharmaceutical
NAICS : 325411
SIC : 2834
ISIN : KR7001062009
Share Class Description:
XKRX:001067: Pfd Shs Non-VotingCompare
Compare
Traded in other countries / regions
001060.Korea IPO Date
1976-06-14Description
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.72 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | 1.6 | |||||
| Interest Coverage | 8.22 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 3.01 | |||||
| Beneish M-Score | -2.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.8 | |||||
| 3-Year EBITDA Growth Rate | 82.7 | |||||
| 3-Year FCF Growth Rate | -0.4 | |||||
| 3-Year Book Growth Rate | 7.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.87 | |||||
| 9-Day RSI | 38.02 | |||||
| 14-Day RSI | 40.37 | |||||
| 6-1 Month Momentum % | -2.9 | |||||
| 12-1 Month Momentum % | -4.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | |||||
| Quick Ratio | 0.94 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 100.48 | |||||
| Days Sales Outstanding | 74.11 | |||||
| Days Payable | 60.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.68 | |||||
| Dividend Payout Ratio | 0.23 | |||||
| 3-Year Dividend Growth Rate | 11.1 | |||||
| Forward Dividend Yield % | 0.68 | |||||
| 5-Year Yield-on-Cost % | 0.96 | |||||
| 3-Year Average Share Buyback Ratio | -0.6 | |||||
| Shareholder Yield % | 9.18 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.36 | |||||
| Operating Margin % | 14.12 | |||||
| Net Margin % | 5.5 | |||||
| FCF Margin % | 12.11 | |||||
| ROE % | 16.03 | |||||
| ROA % | 6.32 | |||||
| ROIC % | 16.2 | |||||
| ROC (Joel Greenblatt) % | 28.32 | |||||
| ROCE % | 21.9 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.53 | |||||
| PE Ratio without NRI | 16.26 | |||||
| Shiller PE Ratio | 248.26 | |||||
| Price-to-Owner-Earnings | 10.22 | |||||
| PS Ratio | 0.94 | |||||
| PB Ratio | 2.45 | |||||
| Price-to-Tangible-Book | 2.74 | |||||
| Price-to-Free-Cash-Flow | 7.82 | |||||
| Price-to-Operating-Cash-Flow | 5.85 | |||||
| EV-to-EBIT | 10.05 | |||||
| EV-to-EBITDA | 7.84 | |||||
| EV-to-Revenue | 0.98 | |||||
| EV-to-FCF | 7.85 | |||||
| Price-to-Projected-FCF | 1.08 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Graham-Number | 1.41 | |||||
| Price-to-Net-Current-Asset-Value | 224.73 | |||||
| Earnings Yield (Greenblatt) % | 9.96 | |||||
| FCF Yield % | 13.21 | |||||
| Forward Rate of Return (Yacktman) % | -1.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JW Pharmaceutical Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 755,736.93 | ||
| EPS (TTM) (â‚©) | 1634.702 | ||
| Beta | 0.27 | ||
| Volatility % | 11.06 | ||
| 14-Day RSI | 40.37 | ||
| 14-Day ATR (â‚©) | 494.317569 | ||
| 20-Day SMA (â‚©) | 59045 | ||
| 12-1 Month Momentum % | -4.73 | ||
| 52-Week Range (â‚©) | 51666.666666 - 64803.921568 | ||
| Shares Outstanding (Mil) | 23.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JW Pharmaceutical Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JW Pharmaceutical Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
JW Pharmaceutical Frequently Asked Questions
What is JW Pharmaceutical(XKRX:001067)'s stock price today?
The current price of XKRX:001067 is â‚©58700.00. The 52 week high of XKRX:001067 is â‚©64803.92 and 52 week low is â‚©51666.67.
When is next earnings date of JW Pharmaceutical(XKRX:001067)?
The next earnings date of JW Pharmaceutical(XKRX:001067) is .
Does JW Pharmaceutical(XKRX:001067) pay dividends? If so, how much?
The Dividend Yield %  of JW Pharmaceutical(XKRX:001067) is 0.68% (As of Today), Highest Dividend Payout Ratio of JW Pharmaceutical(XKRX:001067) was 4.85. The lowest was 0.23. And the median was 0.79. The  Forward Dividend Yield % of JW Pharmaceutical(XKRX:001067) is 0.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers